MinorEstrogens – natural and semisynthetic×Angiotensin II receptor blocker (ARB, sartan)
Updated · Methodology
Mechanism
CYP3A4 partly metabolises estradiol, so inducers and inhibitors of this enzyme may affect its metabolism (estradiol tablets label, US Food and Drug Administration, FDA). Irbesartan is metabolised in the liver by glucuronide conjugation and oxidation, mainly by CYP2C9, and the contribution of CYP3A4 is negligible (Aprovel SmPC, European Medicines Agency, EMA). Based on in vitro data, no interaction is expected between irbesartan and drugs whose metabolism depends on CYP3A4 (Avapro label, FDA). The irbesartan documents warn about other antihypertensives, drugs that raise potassium, lithium and non-steroidal anti-inflammatory drugs, but not about oestrogens (Aprovel SmPC, EMA; Avapro label, FDA).
Symptoms
The documents describe no symptoms linked to this combination. During hormone replacement therapy, blood pressure sometimes rises slightly, but clinically relevant increases are rare. Oestrogens can cause fluid retention (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With volume or sodium depletion, irbesartan can cause symptomatic hypotension, especially after the first dose. It can also raise potassium, especially with renal impairment, overt proteinuria from diabetic nephropathy or heart failure (Aprovel SmPC, European Medicines Agency, EMA).
Management
According to the documents, the doses of estradiol and irbesartan need no change. No document names the pair, and the metabolic pathways of the two drugs do not overlap (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Aprovel SmPC, European Medicines Agency, EMA; estradiol tablets and Avapro labels, US Food and Drug Administration, FDA). Irbesartan is used for hypertension, and hypertension is on the list of conditions that need close supervision in women taking hormone replacement therapy (Progynova SmPC, AEMPS). Blood pressure is monitored at regular intervals during oestrogen use (estradiol tablets label, FDA). If clinically significant sustained hypertension develops during hormone replacement therapy, stopping the therapy is considered, and a significant rise in blood pressure is a reason to stop it immediately (Progynova SmPC, AEMPS). Oestrogens can cause fluid retention, so women with renal or cardiac disorders are closely monitored (Progynova SmPC, AEMPS). When irbesartan is used in renal impairment, serum potassium and creatinine are checked periodically (Aprovel SmPC, EMA). Sodium or volume depletion from diuretics, a salt-restricted diet, diarrhoea or vomiting is corrected before irbesartan is started (Aprovel SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Estradiol (nº registro 47814), sección 4.5 (2026)– AEMPS, CIMA, nº registro 47814, revisión 02/2026, sección 4.5
- AEMPS: Ficha técnica: Estradiol, Progynova 1 mg (nº registro 47814), sección 4.4 (2026)– AEMPS, CIMA, nº registro 47814 (Progynova 1 mg comprimidos recubiertos, Bayer Hispania), revisión 02/2026, secciones 4.1, 4.4 y 4.5
- FDA: Estradiol tablets, Teva (estradiol) prescribing information (2024)– FDA, DailyMed setid c4936878-1643-4e7f-9b0d-e4957935aef2 (Teva Pharmaceuticals USA), revisión 02/2024 (versión 16), CLINICAL PHARMACOLOGY (Drug Interactions), PRECAUTIONS (Fluid retention, Exacerbation of other conditions)
- EMA: Ficha técnica: Irbesartán – Aprovel (EU/1/97/046), sección 4.5 (2026)– EMA, SmPC Aprovel 150 mg comprimidos recubiertos con película (EU/1/97/046, Sanofi Winthrop Industrie), texto en CIMA nº 97046022, consultado 03.11.2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4, 4.5 y 5.2
- FDA: Avapro (irbesartan) prescribing information (2026)– FDA, DailyMed setid 7885b2a8-be4e-48ab-8113-4e6ab791eb98 (Sanofi-Aventis U.S.), revisión 08/2026 (versión 22), secciones 4, 5, 7 y 12.3